Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Kowa’s Biz Realignment Reflects Globalization, Workstyle Reform, but No Job Cull Planned: President
February 27, 2019
- Roche Diagnostics Files PD-L1 Expression Assay for Use in Breast Cancer in Japan
February 27, 2019
- FunPep Gets Green Light for Clinical Study in Australia of Antibody-Inducing Peptide for Psoriasis
February 27, 2019
- Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
- Epclusa Hits Japan Market, 1st Drug for Hep C with Decompensated Cirrhosis
February 26, 2019
- Kentaro Murakawa Named as New President for Daiichi Sankyo Espha
February 26, 2019
- Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
- Shionogi Grabs European Nod for Naldemedine
February 25, 2019
- Daiichi Sankyo to Shake Up Organizations Focusing on Oncology R&D
February 25, 2019
- SanBio Vows to Continue Development of Stem Cell Therapy SB623 despite Setback: President
February 25, 2019
- Kyowa, Yoshitomi to Copromote Bipresso in Japan
February 22, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
- Japan Pharma Market Down 1.7% in 2018, with Maviret as Top-Selling Product: IQVIA Data
February 21, 2019
- Janssen Files Protease Inhibitor/NRTIs Combo for HIV Infection in Japan
February 21, 2019
- Ono/Seikagaku’s Novel Osteoarthritis Drug Hits Primary Goal in Japan PIII
February 20, 2019
- EA Pharma Grabs Japan Rights to Dr. Falk’s Liver Therapy
February 20, 2019
- Suzuken, Toho to Set Up Generic JV, Share Systems in Specialty Pharma Business
February 20, 2019
- Shionogi, FunPep Link to Joint Research for Antibody-Inducing Peptides in Pain Field
February 19, 2019
- Taiyo Forms Capital Alliance with Regenerative Medicine Biotech
February 19, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…